Cargando…
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial
BACKGROUND: We have previously shown lymphocyte density, measured using computational pathology, is associated with pathological complete response (pCR) in breast cancer. The clinical validity of this finding in independent studies, among patients receiving different chemotherapy, is unknown. PATIEN...
Autores principales: | Ali, H. R., Dariush, A., Thomas, J., Provenzano, E., Dunn, J., Hiller, L., Vallier, A.-L., Abraham, J., Piper, T., Bartlett, J. M. S., Cameron, D. A., Hayward, L., Brenton, J. D., Pharoah, P. D. P., Irwin, M. J., Walton, N. A., Earl, H. M., Caldas, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834010/ https://www.ncbi.nlm.nih.gov/pubmed/28525534 http://dx.doi.org/10.1093/annonc/mdx266 |
Ejemplares similares
-
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
por: Earl, H. M., et al.
Publicado: (2017) -
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer
por: Ali, H. Raza, et al.
Publicado: (2016) -
A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial
por: Provenzano, E, et al.
Publicado: (2013) -
Astronomical algorithms for automated analysis of tissue protein expression in breast cancer
por: Ali, H R, et al.
Publicado: (2013) -
The challenges of using radiological ‘tumour response' as an outcome: lessons learned from neo-tango and artemis, two neo-adjuvant chemotherapy breast cancer trials
por: Hiller, Louise, et al.
Publicado: (2013)